Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

NCT07539311 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT07539311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07539311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers
Lead sponsor
Genmab
Phase
Phase 2
Overall status
Recruiting
Start date
May 11, 2026
Completion date
November 30, 2028
Enrollment
160 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal cancers